Literature DB >> 19022101

Cutaneous drug eruptions: a 5-year experience.

Deborah Gerson1, Vathany Sriganeshan, John B Alexis.   

Abstract

BACKGROUND: The diversity of cutaneous drug eruptions encompasses many clinicopathologic entities.
METHODS: Cases with a pathologic diagnosis of drug eruption from 2000 to 2005 were retrieved from our institution. The histologic slides were reviewed, the patterns of inflammatory changes were recorded, and a chart review was performed.
RESULTS: The majority of the cases (94%) were "morbilliform"-type rashes. Eighty-two percent of cases exhibited an inflammatory infiltrate confined to the superficial dermis. Eighty percent exhibited a perivascular and interstitial pattern of dermal infiltrate. The infiltrate was composed of lymphocytes and eosinophils in approximately 29% of cases, lymphocytes and neutrophils in approximately 10% of cases, and lymphocytes, eosinophils, and neutrophils in approximately 21% of cases. Eosinophils were present in only 50% of cases. Approximately half (53%) of the cases exhibited epidermal-dermal interface changes. LIMITATIONS: The cases were limited to those with a pathologic diagnosis of cutaneous drug reaction, thereby excluding any cases with drug-induced disease not specifically diagnosed (histologically) as such.
CONCLUSIONS: While the histologic features of most drug eruptions are not entirely specific, the finding of superficial infiltrates composed variably of lymphocytes, neutrophils, and eosinophils, either with or without interface changes, should suggest the possibility of a morbilliform drug eruption. Clinical correlation is very helpful to confirm the diagnosis. To our knowledge, this study is the most extensive documenting the histologic findings in morbilliform drug eruptions.

Entities:  

Mesh:

Year:  2008        PMID: 19022101     DOI: 10.1016/j.jaad.2008.09.015

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  9 in total

1.  Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B.

Authors:  Jeong Tae Kim; Hye Won Jeong; Ki Hwa Choi; Tae Young Yoon; Nohyun Sung; Young Ki Choi; Eun Ha Kim; Hee Bok Chae
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

2.  Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia.

Authors:  Aruna Gavini; Gladys H Telang; Adam J Olszewski
Journal:  Int J Hematol       Date:  2012-03       Impact factor: 2.490

3.  Defining Drugs that are High-Risk Associations for Drug Reactions Within the Hospital Setting.

Authors:  Ty Gilkey; John Trinidad; Claire Kovalchin; Abena Minta; Misha Rosenbach; Benjamin H Kaffenberger
Journal:  J Clin Aesthet Dermatol       Date:  2022-06

Review 4.  Eosinophilic Drug Allergy.

Authors:  Merin Kuruvilla; David A Khan
Journal:  Clin Rev Allergy Immunol       Date:  2016-04       Impact factor: 10.817

5.  Causality assessment of cutaneous adverse drug reactions.

Authors:  Young-Min Son; Jong-Rok Lee; Joo-Young Roh
Journal:  Ann Dermatol       Date:  2011-11-03       Impact factor: 1.444

6.  Morbilliform drug eruptions caused by trimethoprim-sulfamethoxazole.

Authors:  Daisuke Takenaka; Toshinori Nishizawa
Journal:  BMJ Case Rep       Date:  2020-09-23

Review 7.  Histopathology of drug eruptions - general criteria, common patterns, and differential diagnosis.

Authors:  Wolfgang Weyers; Dieter Metze
Journal:  Dermatol Pract Concept       Date:  2011-01-31

8.  Cutaneous adverse drug reactions in patients with peripheral blood eosinophilia during antituberculosis treatment.

Authors:  Tae-Ok Kim; Hong-Joon Shin; Yu-Il Kim; Sung-Chul Lim; Young-Il Koh; Yong-Soo Kwon
Journal:  Korean J Intern Med       Date:  2019-03-19       Impact factor: 2.884

Review 9.  Histopathologic Features of Maculopapular Drug Eruption.

Authors:  Madison Ernst; Alessio Giubellino
Journal:  Dermatopathology (Basel)       Date:  2022-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.